Compugen (CGEN) COM701/Nivolumab Combo Now Boasts a Confirmed CR - Stifel

February 26, 2021 6:42 AM EST Send to a Friend
Stifel analyst Stephen Willey reiterated a Buy rating and $19.00 price target on Compugen (NASDAQ: CGEN) after Management provided an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login